01.23.08
AAIPharma's sterile manufacturing plant in Charleston, SC received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilized products. The approval follows a $1.5 million renovation of the plant and allows for production of products for shipment to countries in the EU. The site previously received FDA approval.
"This investment and subsequent MHRA approval of our Charleston plant is very much in line with AAIPharma's goal to deliver high quality pharmaceutical services to meet the needs of the pharmaceutical and biotechnology industries," stated Lee Karras, senior vice president of global pharmaceutical services at AAIPharma.
"This investment and subsequent MHRA approval of our Charleston plant is very much in line with AAIPharma's goal to deliver high quality pharmaceutical services to meet the needs of the pharmaceutical and biotechnology industries," stated Lee Karras, senior vice president of global pharmaceutical services at AAIPharma.